The criteria for selecting two additional Mab isolates were as follows: (1) they needed to be isolated recently from patients with lung infection in comparison to ATCC 19977, which was isolated in 1950 from a knee abscess, (2) one needed to be susceptible to most drugs included in the current Mab disease treatment guidelines, and (3) the other needed to be resistant to macrolides, one of the most commonly used classes of antibiotics used to treat Mab disease that, like EBO, is a protein synthesis inhibitor. Here, PROS1 is linked to glycogen storage disease VI.